NO

NovMetaPharma Co., Ltd.

Develops first-in-class drugs and supplements for metabolic and fibrotic diseases.

229500 | KO

Overview

Corporate Details

ISIN(s):
KR7229500004
LEI:
Country:
South Korea
Address:
서울특별시 강남구 언주로 727 13층 (논현동, 트리스빌딩), 강남구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NovMetaPharma Co., Ltd. is a biopharmaceutical company specializing in the research, development, and commercialization of first-in-class drugs for metabolic and fibrotic diseases. The company focuses on creating novel treatments with differentiated mechanisms to address significant unmet medical needs. Its core pipeline includes therapeutic candidates for conditions such as type 2 diabetes, obesity, chronic kidney disease, and fibrosis, with lead assets including Cyclo-Z and CHP. In addition to its primary focus on drug development, the company also develops health supplements and sells related raw materials.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-05-15 00:00
Regulatory News Service
기업설명회(IR)개최결과
Korean 6.6 KB
2025-05-13 00:00
Regulatory News Service
특허권취득(자율공시)
Korean 4.8 KB
2025-04-29 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-03-31 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 170.5 KB
2025-03-25 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.3 KB
2025-03-24 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 20.3 KB
2025-03-24 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 22.1 KB
2025-03-14 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 361.6 KB
2025-03-13 00:00
Audit Report / Information
감사보고서제출
Korean 9.4 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 11.0 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 238.9 KB
2025-03-06 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 66.1 KB
2025-02-05 00:00
Regulatory News Service
특허권취득(자율공시)
Korean 5.6 KB
2024-12-20 00:00
Report Publication Announcement
기업설명회(IR)개최결과
Korean 6.7 KB
2024-12-17 00:00
Regulatory News Service
특허권취득(자율공시)
Korean 6.1 KB

Automate Your Workflow. Get a real-time feed of all NovMetaPharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NovMetaPharma Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NovMetaPharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

BOIRON Logo
Global manufacturer of homeopathic medicines for pain relief and flu-like symptoms, sold worldwide.
France
BOI
Bon Natural Life Ltd Logo
Bio-manufactures natural plant ingredients for fragrances, supplements, and immunity solutions.
United States of America
BON
Bosnalijek d.d. Sarajevo Logo
Global manufacturer of drugs for digestive, metabolic, and cardiovascular health.
Bosnia and Herzegovina
BSNL
Boundless Bio, Inc. Logo
Developing ecDNA-directed therapies for intractable oncogene amplified cancers.
United States of America
BOLD
BridgeBio Oncology Therapeutics, Inc. Logo
Clinical-stage biopharma creating small molecule drugs for RAS-dependent cancers.
United States of America
BBOT
BridgeBio Pharma, Inc. Logo
Develops transformative medicines for genetic diseases and genetically driven cancers.
United States of America
BBIO
BRIGHT MINDS BIOSCIENCES INC. Logo
Developing next-gen serotonergic drugs for neurological and psychiatric disorders like epilepsy.
United States of America
DRUG
BRISTOL MYERS SQUIBB CO Logo
Develops innovative medicines for oncology, immunology, and cardiovascular diseases.
United States of America
BMY
R&D pharma firm developing drugs for CNS disorders, oncology, and metabolic diseases.
South Korea
003000
Burning Rock Biotech Ltd Logo
Offers NGS-based diagnostics for precision oncology, from detection to clinical trial support.
United States of America
BNR

Talk to a Data Expert

Have a question? We'll get back to you promptly.